{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046110","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.919558+00:00","generated_at":"2026-05-24T03:38:46.126924+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"confidence":"high","headline":"Plus Therapeutics reports 2024 net loss of $13.0M, cash $3.6M; raised $15M in private placement","bullets":["Cash and investments $3.6M at Dec 31, 2024 vs $8.6M at Dec 31, 2023.","Net loss $13.0M ($1.95 per share) in 2024 vs $13.3M ($4.24 per share) in 2023; operating loss $14.7M.","Raised $15.0M via private placement, regains Nasdaq compliance and extends runway into 2026.","FDA agreed on brand name REYOBIQ; orphan drug designation for leptomeningeal metastases in lung cancer.","Appointed Dr. Michael Rosol as Chief Development Officer; Russell Bradley as President/GM of CNSide Diagnostics."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046110","json":"https://secwatch.observer/filing/0000950170-25-046110.json","markdown":"https://secwatch.observer/filing/0000950170-25-046110.md","text":"https://secwatch.observer/filing/0000950170-25-046110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017025046110/0000950170-25-046110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017025046110/pstv-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:38:46.126924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}